Becton Dickinson & Co., founded in 1897 and headquartered in Franklin Lakes, New Jersey, is a global leader in medical technology aimed at advancing healthcare outcomes. The company develops and manufactures a wide range of medical devices, instrument systems, and reagents, prominently known for its innovations in diabetes care, medication management, and infection prevention.
| Bond Name | Country | Maturity | Coupon(%) | |||
|---|---|---|---|---|---|---|
| No data found! | ||||||
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Becton Dickinson began issuing bonds in the mid-1980s, establishing a robust history of debt financing to support its strategic growth initiatives. Notably, in 2017, the company issued $2.3 billion in bonds to finance its acquisition of C.R. Bard, enhancing its portfolio in vascular access and surgical specialties. As of October 2023, the company’s bond yields are competitive within the healthcare industry, reflecting its strong credit rating and stable financial position. Recent highlights include a successful $1 billion issuance in April 2023, which featured a 10-year maturity and attracted significant investor interest, reflecting confidence in Becton Dickinson's long-term growth trajectory.